Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2019)
Arbutus Biopharma (ABUS) posted Cash from Restructuring of -$66000.0 for Q4 2019, up 52.17% sequentially from -$138000.0 in Q3 2019, and down 111.76% YoY from $561000.0 in Q4 2018.
Powered by 
Analysis
Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2019) Analysis & Trends
Arbutus Biopharma has reported Cash from Restructuring for 2 years, with the latest figure at -$66000.0 in Q4 2019.
- Quarterly Cash from Restructuring fell 111.76% year-over-year to -$66000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was -$983000.0 (down 159.04% YoY) and the FY2019 annual result came in at -$983000.0, down 173.85% from the prior year.
- Cash from Restructuring improved to -$66000.0 in Q4 2019 per ABUS's latest filing, from -$138000.0 in the prior quarter.
- Over five years, Cash from Restructuring peaked at $1.0 million in Q1 2018 and troughed at -$640000.0 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Arbutus Biopharma | 1.02 Bn | 927.31 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -66,000.00 |
| Sep 30, 2019 | -138,000.00 |
| Jun 30, 2019 | -640,000.00 |
| Mar 31, 2019 | -139,000.00 |
| Dec 31, 2018 | 561,000.00 |
| Sep 30, 2018 | -320,000.00 |
| Jun 30, 2018 | 61,000.00 |
| Mar 31, 2018 | 1.03 Mn |